Bruker Corporation (BRKR)

NMS – Real vaqt narxi. Valyuta: USD

57.55

+0.53 (0.93%)

Bozor ochiq: Aug 12, 2026, 1:14 PM EDT

57.02

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY sc.

10.08.2026

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker's post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human ph.

04.08.2026

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

04.08.2026

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

04.08.2026

Bruker Q2 Earnings Call Highlights

Bruker NASDAQ: BRKR reported second-quarter revenue growth and expanded profitability as demand improved for scientific instruments, particularly in biopharma and several “deep tech” markets including semiconductor metrology, security detection and energy research.

04.08.2026

Bruker (BRKR) Q2 Earnings Beat Estimates

Bruker (BRKR) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.32 per share a year ago.

04.08.2026

Bruker Reports Second Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieve.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

10.08.2026

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

04.08.2026

Bruker Corporation (BRKR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bruker Corporation (BRKR)

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bruker Q2 Earnings Call Highlights

Bruker (BRKR) Q2 Earnings Beat Estimates

Bruker Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Reports Second Quarter 2026 Financial Results

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bruker Q2 Earnings Call Highlights

Bruker (BRKR) Q2 Earnings Beat Estimates

Bruker Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Reports Second Quarter 2026 Financial Results

Search stocks

Bruker Corporation (BRKR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bruker Corporation (BRKR)

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bruker Q2 Earnings Call Highlights

Bruker (BRKR) Q2 Earnings Beat Estimates

Bruker Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Reports Second Quarter 2026 Financial Results

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript

Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bruker Q2 Earnings Call Highlights

Bruker (BRKR) Q2 Earnings Beat Estimates

Bruker Reports Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Reports Second Quarter 2026 Financial Results